Handa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
December 26, 2023 at 02:26 pm IST
Share
Handa Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 240.03 million compared to TWD 6.91 million a year ago. Net income was TWD 146.03 million compared to net loss of TWD 20.88 million a year ago. Basic earnings per share from continuing operations was TWD 1.07 compared to basic loss per share from continuing operations of TWD 0.16 a year ago. Diluted earnings per share from continuing operations was TWD 1.07 compared to diluted loss per share from continuing operations of TWD 0.16 a year ago.
For the nine months, sales was TWD 806.29 million compared to TWD 47.87 million a year ago. Net income was TWD 640.06 million compared to net loss of TWD 107.26 million a year ago. Basic earnings per share from continuing operations was TWD 4.84 compared to basic loss per share from continuing operations of TWD 0.86 a year ago. Diluted earnings per share from continuing operations was TWD 4.83 compared to diluted loss per share from continuing operations of TWD 0.86 a year ago.
Handa Pharmaceuticals Inc is a Taiwan-based pharmaceutical company focused on the development of niche drug. The Company integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The Company's products are mainly sold to the United States, Canada and India.